Profitability
Weight: 25%
F
0
- 5yr Avg ROIC -16.3%
- Operating Margin Trend -1661.44 pp/yr
ARWR
Arrowhead Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -95.6%
- 5yr Share-Count CAGR 5.8%
Growth Quality
Weight: 25%
A
88
- 5yr Revenue CAGR 56.6%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -3421.5%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
B+
76
- Net Debt / EBITDA -3.36x
- Interest Coverage (EBIT/Int) 1.58x
- Altman Z-Score 8.22
Stability
Weight: 5%
B-
64
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 6
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 5 gurus held; 1 added; 2 trimmed; 2 full exits.
- Holders
- 3 -2
- Avg Δ position
- -37.4%
- New buys
- 0
- Full exits
- 2
- Dalio sold -100%
- Laffont sold -100%
- Greenblatt decreased -82%